Vertex Pharmaceuticals (VRTX) experienced a -1.37% stock decline in the latest trading session, despite a 6.21% gain over the previous month. The company is preparing for upcoming financial results, with analysts expecting earnings of $4.19 per share and revenue of $2.81 billion. Currently holding a Zacks Rank of #3 (Hold), VRTX has a Forward P/E ratio of 28.9, which is higher than its industry average.